GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2006

Open Biosystems Will Validate Gene Silencing Capability of shRNAmir Clones

  • The NCI selected Open Biosystems to verify the effectiveness of lentiviral microRNA-adapted shRNAmir technology in 135 specifically targeted cancer genes. shRNAmir technology is an effective technique to simplify the discovery and validation of tumor suppressor functions.

    With NCI funding, Open Biosystems will functionally validate the knock-down efficiency of shRNAmir lentiviral constructs when targeting specific cancer genes.

    Open Biosystems believes that this study will provide researchers with a validated set of cancer gene targeting reagents and data. In the first quarter of 2007, researchers will be able to access cancer-specific shRNAmir reagents through Open Biosystems and the corresponding knock-down data through the NCI. This in turn can be used to better identify and study the specific genes involved in the development of cancer.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »